Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enphase Energy Inc (ENPH) vs Enveric Biosciences Inc (ENVB) Price & Performance

Enphase Energy IncTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Enphase Energy Inc vs Enveric Biosciences Inc — how do they compare? Enphase Energy Inc trades at $32.77 (market cap $4.35B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: Enphase Energy Inc is far larger — about 639.7× Enveric Biosciences Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Enveric Biosciences Inc for 14 Days on average.

ENPHENVB
Market Cap
$4.35B$6.80M
Volume
5,068,59564,867
Sector
EnergyHealth
52-Week High
$72.33$10.80
52-Week Low
$26.12$1.27
Typical Hold Time
72 Days14 Days
Enterprise Value
$3.99B-$1.49M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enphase Energy Inc

Enphase Energy (ENPH) trades at $33.50, down 1.21% with bearish technical signals and mixed earnings performance. The stock shows declining revenue from $2.3B in 2023 to $1.47B in 2025, though net margins improved to 10.09%. Recent developments include IQ Meter Collar approvals and solid-state transformer production for AI data centers, providing potential growth catalysts amid solar sector volatility.

Outlook remains cautious with analyst consensus at $42.90 (28% upside) but recent earnings misses and high borrowing costs for solar projects pose near-term risks. The stock offers exposure to energy technology innovation but faces competitive pressure and macroeconomic headwinds affecting renewable energy demand.

Enveric Biosciences Inc

ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.

The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ENPH
100% Buy0% Sell
Avg holding period · 72 Days
ENVB

No sentiment data available yet.

Top news

Latest headlines on both assets

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH →

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB →